Lexicon Pharmaceuticals Inc

NASDAQ:LXRX  
4.34
+0.14 (+3.33%)
Products

Lexicon Pharma Receives Fast Track Designation From The FDA For LX9211 For Diabetic Peripheral Neuropathic Pain

Published: 12/11/2020 13:33 GMT
Lexicon Pharmaceuticals Inc (LXRX) - Lexicon Pharmaceuticals Receives Fast Track Designation From the FDA for Lx9211 for Diabetic Peripheral Neuropathic Pain.
Lexicon Pharmaceuticals - Currently Enrolling Patients With Diabetic Peripheral Neuropathic Pain in a Phase 2 Proof-of-concept Study of Lx9211.
Lexicon Pharmaceuticals - Preparing to Initiate a Second Phase 2 Clinical Trial of Lx9211 in Post-herpetic Neuralgia.